According to the National Cancer Institute, 238,598 new cases of prostate cancer will have been diagnosed in 2013. More than 90% of men with symptomatic metastatic castration-resistant prostate cancer (mCRPC) have radiologic evidence of metastasis to bone either on technetium SPECT or sodium fluoride PET/CT bone scan.
In this segment, panelists explore the various treatment options that exist for patients with high-risk localized or advanced prostate cancer, and making the optimal treatment decision, which is likely to require multiple modalities.
In this segment, panelists discuss the Melbourne Consensus Statement on PSA, which was produced by a group of leading prostate cancer experts at the 2013 Prostate Cancer World Meeting held in Melbourne, Australia.
It's almost as if Neal D. Shore, MD, was destined to conduct research, regardless of the path he took to get into the field. Translational researchers developing treatments for cancer are often based at large academic institutions.
Moderator, Raoul S. Concepcion, MD, introduces a panel discussion focused on guidelines and the many new treatments recently approved for castration-resistant prostate cancer.
Steven E. Finkelstein, MD, the national director of Translational Research at 21st Century Oncology, discusses the May 2013 approval of the alpha radiation emitting agent radium-223 dichloride (Xofigo).
Steven E. Finkelstein, MD, National Director of Translational Research, 21st Century Oncology, discusses reimbursement issues with radium-223.
Steven E. Finkelstein, MD, National Director of Translational Research, 21st Century Oncology, discusses the safety profile of Xofigo to treat patients with bone metastases from CRPC.